This is a prospective, multi-center, open-label, phase II clinical trial, aims to assess the
effectiveness of the combination ACVD (Adriamycin, Cyclophosphamide, Vinblastine and
Dacarbazine) and BV (Brentuximab Vedotin) in PET-2 positive advanced-stage HL patients, in
order to improve the overall long-term disease control in the entire cohort of advanced-stage
HL.
Phase:
Phase 2
Details
Lead Sponsor:
King Abdullah International Medical Research Center